{"id":49803,"date":"2022-10-19T15:02:07","date_gmt":"2022-10-19T13:02:07","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/symbiosis-and-healthtech-arkansas-form-bioar-trial-accelerator\/"},"modified":"2022-10-19T15:02:07","modified_gmt":"2022-10-19T13:02:07","slug":"symbiosis-and-healthtech-arkansas-form-bioar-trial-accelerator","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/symbiosis-and-healthtech-arkansas-form-bioar-trial-accelerator\/","title":{"rendered":"SymBiosis and HealthTech Arkansas Form BioAR Trial Accelerator"},"content":{"rendered":"
\n

\nWill provide companies in late pre-clinical to early-clinical stages of development<\/i><\/b> access to <\/i><\/b>high-quality trial sites in Arkansas to bring groundbreaking therapies to market faster<\/i><\/b>\n<\/p>\n

\nDesigned to increase Arkansans\u2019 access to cutting-edge clinical care and innovative medicines<\/i><\/b>\n<\/p>\n

\nApplication now open for inaugural cohort beginning in April 2023<\/i><\/b>\n<\/p>\n

BENTONVILLE, Ark.–(BUSINESS WIRE)–SymBiosis Capital Management, LLC<\/a> (\u201cSymBiosis\u201d) and HealthTech Arkansas<\/a> today announced the formation of BioAR Trial, an accelerator program to help biotherapeutics companies in late pre-clinical stages of development bring groundbreaking therapies to market faster, while increasing Arkansans\u2019 access to cutting-edge clinical care and innovative medicines.\n<\/p>\n

<\/a><\/p>\n

\nSymBiosis and HealthTech Arkansas together are ideally positioned to advance the mission of BioAR Trial. Based in Bentonville, SymBiosis has significant scientific and operational capabilities, financial resources, and experience working with a range of biotherapeutics companies through various phases of growth and development. HealthTech Arkansas has partnerships with the largest hospitals and health systems in Arkansas that it will activate to provide BioAR Trial participating companies with high-quality clinical trial sites in Arkansas that can rapidly enroll diverse populations.\n<\/p>\n

\nCompanies from around the world are invited to apply to participate in BioAR Trial, which will focus on deploying advanced and emerging therapeutic modalities\u2014such as precision medicines, biologics, cell therapies, and genetic medicines\u2014to treat serious and life-threatening diseases in oncology, immune disorders, and cardio-metabolic disease. The application for BioAR Trial is now open through January 15, 2023, at www.bioarkansas.co<\/a>. BioAR Trial\u2019s first cohort of five companies will begin in April 2023.\n<\/p>\n

\n\u201cOur goal at SymBiosis is to make investments that help bring innovative therapeutics to market to improve and save lives,\u201d said Chidozie Ugwumba, Managing Partner of SymBiosis. \u201cWe are pleased to partner with HealthTech Arkansas to make our shared vision of BioAR Trial a reality and expect that this will be the first in a series of initiatives that help transform Arkansas into a national leader in healthcare. We are excited for what we anticipate will be a strong response to this unique opportunity and to begin working with the participating companies to advance their biotherapeutics.\u201d\n<\/p>\n

\n\u201cPartnering with SymBiosis to establish BioAR Trial is an important next step towards achieving our goal of driving innovation for Arkansas healthcare providers through our accelerators and internal innovation programming,\u201d added Jeff Stinson, Director of HealthTech Arkansas. \u201cWe are pleased to couple our healthcare accelerator\u2019s ability to provide high-quality clinical trial sites for promising early-stage companies with SymBiosis\u2019 deep expertise in helping biotherapeutic companies to fulfill their vital missions.\u201d\n<\/p>\n

\n\u201cWe take very seriously the task of helping to accelerate the growth and success of companies developing some of the world\u2019s most-promising therapeutics by streamlining the clinical trial process,\u201d said Jahan Ali, Vice President of Business Development at SymBiosis, who will lead BioAR Trial. \u201cThe combination of SymBiosis and HealthTech Arkansas\u2019 resources and capabilities will enable BioAR Trial to do just that. We are thrilled to welcome our inaugural class of participating companies.\u201d\n<\/p>\n

\nBioAR Trial\u2019s partner hospitals and health systems are:\n<\/p>\n